| Document |
Document Title |
|
JPH04352785A |
PURPOSE: To provide the subject new compound having low toxicity and useful as an antirheumatic agent. CONSTITUTION: The compound of formula I (R1 is 1-4C alkyl; R2 is H or together with R1 forms 2-3C methylene; R3 and R4 are H or 1-4C a...
|
|
JPH0469157B2 |
A sulfate of tetrahydrobiopterin having the formula (I):and a process for preparing the same, which comprises crystallizing tetrahydrobiopterin from an aqueous medium containing sulfuric acid. The sulfate has a high crystallinity of the ...
|
|
JPH04506082A |
A double blind clinical trial of 10-deazaaminopterin versus the antirheumatoid drug methotrexate (MTX) established that 10-deazaaminopterin, in addition to being at least equally effective as methotrexate in all respects in ameliorating ...
|
|
JPH04505007A |
Magnesium folates, process for their preparation, pharmaceutical compositions containing such folates and therapeutical applications where their supply can advantageously correct disorders and various conditions caused by deficiencies an...
|
|
JPH0450314B2 |
Compounds having the structure in which R is -CO-Ar-COOR1 where R1 is hydrogen or lower alkyl, and pharmaceutical compositions containing the same exhibiting high growth inhibitory activity against methotrexate resistant cells.
|
|
JPH04210983A |
PURPOSE: To provide a novel triamterene derivative having excellent diuretic activity to sodium and retaining activity to potassium as parenterally applicable diuretics. CONSTITUTION: A compound of formula I [R is SO3M or formula II; M i...
|
|
JPH0414677B2 |
|
|
JPH0413357B2 |
|
|
JPH047747B2 |
|
|
JPH0380127B2 |
A pharmaceutical composition for the treatment of infantile autism which contains tetrahydrobiopterin or a derivative thereof as a major effective ingredient and 5-hydroxytryptophan and/or L-DOPA as an optional auxiliary effective ingred...
|
|
JPH03279372A |
NEW MATERIAL:The compound of formula I [R1 to R4 are H, alkyl, phenyl, heteroaryl, etc.; R5 is H, alkyl, alkanoyl, etc.; R6 to R8 are H, halogen, alkyl, etc.; X is O or S; Y is O or N-R10 (R10 is H or alkyl); R9 is group of formula II (m...
|
|
JPH03275684A |
NEW MATERIAL:A compound shown by formula I [R1 and R2 are H; R3 is H, alkyl or (substituted) phenylalkyl; R4 and R5 are H, halogen, alkyl, alkoxy, etc. ; X is O or NH; R6 is group shown by formula II (m is 0 or 1) or group shown by formu...
|
|
JPH03264584A |
NEW MATERIAL:A compound expressed by formula I {R1 and R2 are H or alkyl; R3 is H, alkyl or (substituted) phenylalkyl; R4 and R5 are H, halogen, alkyl, (acyl)amino, OH, nitro, etc.; X is O or NH; R6 is formula II (m is 0 or 1), formula I...
|
|
JPH03264570A |
NEW MATERIAL:A compound shown by formula I [R1 and R2 are H or alkyl; R3 is R1, R2 or (substituted)phenylalkyl; R4 and R5 are R1, R2, halogen, alkoxy, amino, OH, nitro, etc.; X is O or NH; R6 is group shown by formula II (m is 0 or 1), g...
|
|
JPH0369890B2 |
L-erythro-5,6,7,8-tetrahydrobiopterin, L-sepiapterin, 1',2'-diacetyl-5,6,7,8-tetrahydrobiopterin and 6-methyl-5,6,7,8-tetrahydropterin can be used for the therapeutic treatment of patients with Parkinson's disease and of patients with de...
|
|
JPH03504860A |
PCT No. PCT/FR89/00257 Sec. 371 Date Jan. 18, 1990 Sec. 102(e) Date Jan. 18, 1990 PCT Filed May 29, 1989 PCT Pub. No. WO89/11280 PCT Pub. Date Nov. 30, 1989.The present invention relates to a novel use in therapy of a folinic acid substa...
|
|
JPH03232853A |
NEW MATERIAL:A compound expressed by formula I {R1 is H or 1-6C alkyl; R2 is R1, halogen, carboxyl, 1-6C alkoxy, carbamoyl, amino, nitro or sulfo, etc.; R3 and R4 are R1, 3-6C cycloalkyl or expressed by formula IV [Ar is (substituted)ary...
|
|
JPH0361671B2 |
An improved process for the purification of crude riboflavin which has been prepared by condensation of an N-(D)-ribityl-2-arylazo-4,5-dimethylaniline and barbituric acid or another N-(D)-ribityl-4,5-dimethyl-aniline derivative with a ba...
|
|
JPH0361672B2 |
Riboflavin of the formula I (I) is prepared by condensing a 4,5-dimethyl-N-(D)-ribityl-2-phenylazoaniline of the formula II (II) where R is H or -Cl, -NO2 or -CH3 in the o- or p-position, with barbituric acid of the formula III (III) in ...
|
|
JPH03503420A |
A compound having the structure in which R1 is hydrogen or a lower alkyl group and R2 is hydrogen or methyl.
|
|
JPH0340029B2 |
A process and composition are provided employing 10-deazaminopterin and 10-alkyl derivatives therefor for the treatment of leukemia, as well as other tumor systems including those of ascitic character, and also a process for preparing 10...
|
|
JPH0338249B2 |
A diuretically active pharmacological composition which comprises 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid (furosemide) together with at least one compound of formula (I) (I) wherein R is a hydrophilic radical, capable of increasi...
|
|
JPH0332553B2 |
|
|
JPH0328200B2 |
|
|
JPH0383984A |
NEW MATERIAL: 5-Methyl-5-deaza-10-propargylaminopterin. USE: Antitumor agent. Superior in antitumor activity. PROCESS: A compound of formula I and a compound of formula II are reacted in N,N-dimethylacetamide at 20-25°C, to obtain N-[4-...
|
|
JPH0366689A |
NEW MATERIAL: A compound of formula I [one or two of A, B, E, D are N, and the other are CR1, and A, E, D are N, B is CR1; R1, R2 are each H, a halogen, a (halo)1-4C alkyl, a (substituted) phenyl or the like; X is O, S, SO, SO2, NR3(R3 i...
|
|
JPH0344377A |
NEW MATERIAL: A compound represented by formula I {wherein Z denotes O, S, or NR (wherein R denotes H or an aliphatic hydrocarbon group); R1 denotes an aliphatic, cycloaliphatic or araliphatic hydrocarbon group; R2 and R3 denote halogen,...
|
|
JPH038355B2 |
The invention provides novel aldehyde adducts of triamterene having improved solubility and bioavailability as compared to triamterene. Pharmaceutical compositions containing the novel adducts and having diuretic activity are also descri...
|
|
JPH034553B2 |
A process and composition are provided employing 10-deazaminopterin and 10-alkyl derivatives therefor for the treatment of leukemia, as well as other tumor systems including those of ascitic character, and also a process for preparing 10...
|
|
JPH0262820B2 |
|
|
JPH0259151B2 |
|
|
JPH02292287A |
NEW MATERIAL: A compound of formula I (wherein A is an optionally substituted 1-8C spacer hydrocarbon group containing a group of formula II attached directly to the phenyl group; R1 is H, a cycloalkyl having up to 7 ring carbon atoms, a...
|
|
JPH0255434B2 |
|
|
JPH02262517A |
PURPOSE: To obtain a safe treating agent for mental disease such as depression containing a pterin derivative as a main ingredient and participated by intracerebral tetrahydrobiopterin. CONSTITUTION: The objective treating agent containi...
|
|
JPH02258731A |
PURPOSE: To obtain a nitrogen-containing heterocyclic compd. easily and efficiently substd. by Cl or Br by halogenating an OH of a nitrogen-containing heterocyclic starting material of which the ring upper position adjacent to a ring nit...
|
|
JPH02256700A |
NEW MATERIAL: A cytotoxic antibody conjugate represented by formula I (wherein m is 1-10, Ab is an antibody recognizing an antigen related to undesired cells or its fragment, x is a group represented by formula II (R is H or phenyl and n...
|
|
JPH02256676A |
NEW MATERIAL: A pteridines and an acid-added salt thereof represented by formula I, wherein (n) is 0 or 1; R3 is 2-4C alkyl having one or two C excluding C adjacent to N and substituted with OH; R4 is 1-4C alkyl having C excluding C adja...
|
|
JPH02247566A |
PURPOSE: To enable easily, quickly and safely denaturating serum protein by processing serum sample before analyzing with microwave at the high dial. CONSTITUTION: A serum sample to be analyzed is arranged in a microwave oven and exposed...
|
|
JPH02245028A |
PURPOSE: To obtain therapeutic effect in curing mouse leukemia by using an ester obtd. by reacting methotrexate with a biocompatible water-soluble hydroxylated polymer as the active component. CONSTITUTION: A z-antitumor drug (methotrexa...
|
|
JPH0232358B2 |
A modifying agent for a conductive substrate comprises a flavin derivative. A flavin-modified electrode obtained through modification by the modifying agent is capable of reducing an electron transfer protein having a standard oxidation-...
|
|
JPH0231720B2 |
|
|
JPH0212475B2 |
A process for preparing tetrahydrobiopterin which is rich in the (6R)-form, which comprises hydrogenating L-erythrobiopterin in a basic medium in the presence of a platinum group catalyst. According to the process, tetrahydrobiopterin im...
|
|
JPH0278679A |
NEW MATERIAL:A riboflavin derivative expressed by the formula (M is alkaline metal atom). USE: Having vitamin B2 acid activity, useful in the field of medicines, etc., effectively used as a controlling agent for red tide and capable of e...
|
|
JPH02500518A |
Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure wherein: A is +TR and R1, R2, R3, R4, ...
|
|
JPH0245473A |
NEW MATERIAL: A compd. represented by formula I [wherein R1 and R2 are each H, a 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, 1-4C alkoxycarbonyl-1-3C alkyl or R1 and R2 form a heterocycle represented by formula II (a; 1-3) together with N to...
|
|
JPH0149245B2 |
|
|
JPH01186887A |
(57) [Abstract] Since this gazette is application data in front of an electronic application, the data of an abstract is not recorded.
|
|
JPH0133473B2 |
|
|
JPH01165586A |
NEW MATERIAL: A compound of formula I [D is anti-tumor drug moiety having pendant the backbone, which is bonded to the disulfide benzyloxycarbonyl group, formula R1NH (R1 is drug moiety), etc.; R3 is (substituted) 1-10C alkyl, (substitut...
|
|
JPH01151518A |
PURPOSE:To obtain the title compound having improved fluidity, miscibility with other agent and storage stability and useful as a raw material for the direct tableting of tablet, etc., or an additive for food or feed, by spray-drying a d...
|
